BACKGROUND: Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by mutations in the tumor-suppressor gene TP53. Osteosarcoma is a sentinel cancer in LFS. Prior studies using Sanger sequencing platforms have demonstrated that 3% of individuals with osteosarcoma harbor a mutation in TP53. New data from next-generation sequencing have demonstrated that 3.8% of patients with osteosarcoma have a known pathogenic variant, and an additional 5.7% carry exonic variants of unknown significance in TP53. METHODS: Pediatric oncologists were e-mailed an anonymous 18-question survey assessing their willingness to offer TP53 germline testing to a child with osteosarcoma with or without a family history, and they were evaluated for changes in their choices with the prior data and the new data. RESULTS: One hundred seventy-seven pediatric oncologists (22%) responded to the survey. Respondents were more likely to offer TP53 testing to a patient with a positive family history (77.4% vs 12.4%; P < .0001). Significantly more providers responded that they would offer TP53 testing once they were provided with the new data (25.4% vs 12.4%; P 5 .0038). The proportion of providers who responded that they were unsure increased significantly when they were presented with the new data (25.4% vs 10.2%; P 5 .0002). Potential implications for other family members and the possibility that surveillance imaging would detect new malignancies at an earlier stage were important factors influencing a provider's decision to offer TP53 testing. CONCLUSIONS: Recent data increase the proportion of providers willing to offer testing, and this suggests concern on the part of pediatric oncologists that variants of unknown significance may be disease-defining in rare cancers. Cancer 2018;124:1242-50. V C 2018 American Cancer Society.
INTRODUCTION
Advances in genetic technologies are enabling the rapid detection of several heritable disorders associated with an increased risk of childhood cancer, such as Li-Fraumeni syndrome (LFS). 1 LFS is a dominantly inherited cancer predisposition syndrome and is caused in the majority of cases by germline mutations in the TP53 tumor-suppressor gene. 2 LFS is characterized by an increased risk for the development of osteosarcoma, soft tissue sarcoma, premenopausal breast cancer, central nervous system tumors, adrenocortical carcinoma, leukemia, and other neoplasms. Malignancy typically occurs at a younger age in individuals with LFS in comparison with the general population, and individuals with LFS are prone to developing second malignant neoplasms. 3 Osteosarcoma, one of the sentinel cancers of LFS, is the most common primary bone malignancy in childhood and young adults. In the past, McIntyre et al 4 reported that the frequency of germline TP53 mutations, based on Sanger sequencing in sporadic osteosarcomas in children 18 years old or younger, was approximately 3%. Because of the limitations of Sanger sequencing, they had a limited capability for detecting all potential variants within the TP53 gene. A recent study sequenced TP53 exons with targeted next-generation sequencing in 765 patients with osteosarcoma, and it revealed that 9.5% of the patients under the age of 30 years with osteosarcoma carried a germline TP53 mutation: 3.8% carried a known disease-causing mutation, and 5.7% carried rare exonic variants of uncertain significance. 5 Patients with these germline TP53 mutations were statistically significantly younger at diagnosis than those without the mutations.
These findings suggest that there may be value in counseling families about possible hereditary predispositions and TP53 mutation testing in young patients with osteosarcoma because these individuals and their family members may be at risk for developing other LFSassociated cancers. In individuals with LFS, a prospective, observational study showed that a clinical surveillance protocol for the detection of asymptomatic neoplasms demonstrated several benefits, including a survival advantage. 6 Both McIntyre et al 4 and Mirabello et al 5 made some recommendations about the potential value of screening patients with osteosarcoma for TP53 mutations. This contention was supported by Toguchida et al 7 in their review of TP53 mutations in patients with sarcomas. Bougeard et al, 2 in their comprehensive review of families with LFS in France, described the spectrum of disease associated with different mutations, and they suggested the potential for screening based on the severity of the disease predicted by the mutation. Kratz et al 8 summarized the findings of these studies and provided screening recommendations for individuals with LFS. There are currently no established guidelines for screening for TP53 mutations in children with newly diagnosed osteosarcoma.
The current survey was developed to assess provider preferences for TP53 testing because of the recent data demonstrating that 1 in 10 children and young adults with osteosarcoma harbor a TP53 genetic alteration.
MATERIALS AND METHODS

Subjects
The e-mail addresses of 787 practicing pediatric oncologists were obtained via hospital Web sites, published manuscripts, and additional Web sites available in the public domain. Pediatric oncologists were e-mailed a link to an anonymous (IP address-tracked) survey on SurveyMonkey (Palo Alto, California). Nonrespondents were sent 2 subsequent e-mails requesting participation.
Survey Instrument
The survey tool included 18 questions describing clinical scenarios designed to address a pediatric oncology provider's willingness to offer germline TP53 mutation testing to children with osteosarcoma if the prevalence of TP53 mutations was 4% (prior data) versus 10% (new data). We used 4% for the sake of consistency between scenarios involving the data of McIntyre et al 4 and Mirabello et al. 5 Four scenarios were provided in the survey, and all involved the same patient, a 15-year-old boy with a recent diagnosis of osteosarcoma of the left distal femur. The first 2 scenarios were control cases and were included to assess the baseline provider willingness to test children with newly diagnosed osteosarcoma with or without a significant family history. The subsequent 2 cases presented the same 15-year-old boy with no family history with the inclusion of the prior data and the new data (Table 1) . Additional questions were included to assess factors associated with provider preferences for TP53 testing. The complete survey is included in the online supporting information.
Statistical Analysis
The primary endpoint was to assess the effect of recently published data on provider views on offering TP53 testing to patients with osteosarcoma. Data were presented as frequencies and percentages. Associations of provider demographic characteristics with provider views on TP53 mutation screening practices were evaluated with the chisquare test or Fisher's exact test. McNemar's test was used to examine changes in the rates of providers' willingness to offer TP53 testing with the inclusion of the prior data and the new data in comparison with the baseline case. Generalized linear mixed models with a participantspecific random effect to account for within-participant correlation and a logit link function were used to examine effects of the prior and new data on providers' willingness to offer TP53 testing, with adjustments for provider characteristics. All statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, North Carolina). A 2-tailed P value < .05 was considered significant.
RESULTS
Demographics
The survey was sent to 787 pediatric oncologists: 177 responded and 166 responders completed the entire survey for overall response and survey completion rates of 22.5% and 21.1%, respectively. The demographic characteristics of the respondents are described in Table 2 .
Provider Preferences for TP53 Mutation Testing in Patients With Osteosarcoma
Providers elected to offer TP53 testing more frequently to the patient with a first-degree relative with cancer than the same patient with no family history (77.4% vs 12.4%; P < .0001). For the scenario of the patient without a family history, providing the prior data (a germline TP53 mutation rate of approximately 3.5%) was not associated with a significant increase in the rate of providers' willingness to offer testing (20.3% vs 12.4%; P 5 .08). In the same scenario of the patient without a family history, significantly more providers responded that they would offer TP53 testing once they were provided with the new data (25.4% vs 12.4%; P 5 .0038). In addition, the proportion of providers in the scenario of the patient without a family history who responded that they were unsure whether they would offer TP53 testing increased significantly when they were presented with the new data in comparison with the baseline (25.4% vs 10.2%; P 5 .0002; Fig. 1A ).
TP53 Mutation Prevalence and Provider Preference for TP53 Testing
Providers were asked how likely they would be to offer genetic testing if the rate of TP53 mutations was 10% and all these mutations were known to be disease-causing mutations (pathogenic variants). All 45 providers who responded that they were willing to offer testing to the patient with osteosarcoma with the new data also responded that they were likely to offer testing for patients if the mutations constituting the 10% incidence were all known to be diseasecausing mutations (Fig. 1B) . Of the 87 providers who responded that they were not willing to offer testing to the patient with no family history with the new data, 62 (71%) now responded that they were likely to offer testing. Similarly, 80% of the 45 providers who responded that they were unsure about offering testing when they were presented with the new data responded that they were likely to offer testing if all these mutations yielding the 10% rate were known to be disease-causing mutations.
Providers' Considerations When They Are Deciding to Offer TP53 Testing Figure 2A highlights the factors that respondents stated were important in shaping their decision to offer TP53 testing. Fifty-six percent of the participants considered "potential implications for other family members" important, and 55% considered important "the possibility that surveillance imaging for patients with LFS will detect new malignancies at an earlier stage." Other factors that participants indicated were important in their decision making included "concern about provoking potentially unnecessary anxiety around the diagnosis of LFS" and "concern regarding a discussion about the meaning of a variant of unknown significance with a family." When presented with the new data, for respondents who answered yes or were unsure about offering germline mutation testing, the most common reason supporting their decision to offer testing was the possibility that n varies with number of respondents who answered each question.
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surveillance imaging for patients with LFS would detect new malignancies at an earlier stage. However, for those who answered no, the most common reason was the potential implications for other family members (Fig. 2B ).
Factors Associated With Provider Preferences for TP53 Testing
Unlike the overall population, in which providers were more likely to offer testing with the presentation of the new data, respondents who identified themselves as specializing in sarcoma (n 5 40; Table 2 ) showed no significant difference in offering TP53 mutation testing when they were presented with the new data in comparison with the first case of a patient without a family history (17.5% vs 15.0%; P 5 1.0). In addition, there were no significant differences between the sarcoma specialists and the overall group in the willingness to test in the baseline case (15.0% vs 11.8%; P 5 .59) when they were presented with the prior Figure 1 . (A) Percentage of providers willing to offer or unsure about offering germline mutation testing. Providers were significantly more likely to offer testing or were unsure about offering testing as follows: (1) FH versus (2) FH, 91.5% versus 22.6% (P < .0001); (2) FH and prior data versus (2) FH, 37.9% versus 22.6% (P 5 .0025); (2) FH and new data versus (2) FH, 50.8% versus 22.6% (P < .0001); and (2) FH and new data versus (2) FH and prior data, 50.8% versus 37.9% (P 5 .0185). (B) Providers' willingness to offer testing if 10% of children with osteosarcoma had a TP53 mutation associated with Li-Fraumeni syndrome and the mutations in all 10% were known to be disease-causing. Providers who responded that they were willing to test the patient in the (2) FH and new data scenario responded that they were likely to offer testing to 100% of patients if the mutations constituting the 10% incidence were all known to be disease-causing mutations. Seventy-one percent of the providers who responded that they were not willing to test the patient in the (2) FH and new data scenario responded that they were likely to offer testing if the mutations constituting the 10% incidence were all known to be disease-causing mutations. Eighty percent of the providers who responded that they were unsure about offering testing to the patient in the (2) FH and new data scenario responded that they were likely to offer testing if the mutations constituting the 10% incidence were all known to be diseasecausing mutations. data (17.5% vs 19.7%; P 5 .82) or when they were presented with the new data (17.5% vs 28.3%; P 5 .22). Providers at institutions with more than 100 new cancer patients a year (n 5 91; Table 2 ) were significantly more likely to offer testing to the patient with no family history (18.7% vs 5.3%; P < .001) and to the patient with no family history when the prior data were presented (27.5% vs 11.8%; P 5 .01; Fig. 3A) . Providers who spent >60% of their time performing basic research (n 5 39; Table 2 ) were significantly more likely to offer testing to the patient with the prior data (41.0% vs 15.0%; P 5
.001) and with the new data (43.6% vs 20.5%; P 5 .006; Fig. 3B ). In addition, providers working at institutions that had a cancer predisposition clinic (n 5 99; Table 2) were more likely to offer testing when they were presented with the prior data (27.3% vs 11.9%; P 5 .01) and when they were presented with the new data (33.3% vs 14.9%; P5 .01; Fig. 3C ). Finally, providers were more likely to offer germline testing if insurance covered the cost (48.2% vs 16.2%; P < .001). There were no statistically significant differences between provider preferences for offering TP53 testing when stratification was performed (A) Effect of the institutional size on a provider's willingness to offer TP53 mutation testing. Providers working at large institutions were significantly more likely to offer testing as follows: (2) FH, 18.7% versus 5.3% (***P < .0001), and (2) FH and prior data, 27.5% versus 11.8% (*P < .01). There was no statistically significant change in the (2) FH and new data scenario according to the institutional size. (B) Effect of the percentage of time dedicated to basic science research on a provider's willingness to offer TP53 mutation testing. Providers spending >60% versus 0% to 60% of their time doing basic research were significantly more likely to offer testing as follows: (2) FH and prior data, 41.0% versus 15.0% (*P 5 .0012), and (2) FH and new data, 43.6% versus 20.5% (**P < .0062). There was no statistically significant change in the (2) FH scenario according to the percentage of time dedicated to basic research. (C) Effect of the existence of a clinic specializing in patients with cancer predisposition syndromes on a provider's willingness to offer TP53 mutation testing. Providers working in institutions with a clinic specializing in patients with cancer predisposition syndromes were more likely to offer testing as follows: (2) FH and prior data, 27.3% versus 11.9% (*P 5 .01), and (2) FH and new data, 33.3% versus 14.9% (*P 5 .01). There was no statistically significant change in the (2) FH scenario according to the existence of a cancer predisposition clinic. (2) FH indicates negative family history; (1) FH, positive family history. (* 5 P <.05; ** 5 P <.01; *** 5 P <.001). by other demographic variables, including sex, years out of fellowship training, and institutional presence of a genetic counselor.
Bivariate Analysis of Willingness to Test
In a bivariate analysis, institution size, having ordered germline testing for more than 5 patients, working in an institution with a cancer predisposition syndrome clinic, and having genetic counselors available in the institution retained statistical significance in increasing providers' willingness to offer germline testing.
DISCUSSION
In this study, we found that introducing pediatric oncologists to new information about the rate of TP53 alterations in osteosarcoma increased the proportion of providers who reported that they were likely to offer TP53 testing. Likewise, we found that the presentation of the new data also led to greater uncertainty among providers, with more respondents unsure about whether to offer TP53 testing. Because the majority of the respondents stated that they would offer TP53 testing when they were told that all the mutations were pathogenic, this may reflect ambivalence about the clinical significance of variants of unknown significance in the context of a child with a rare cancer. Interestingly, respondents who selfreported specializing in sarcomas, who are likely to be most familiar with these data, did not demonstrate significant differences in their willingness to offer TP53 testing in all 3 scenarios. This may suggest that sarcoma specialists are more confident that these variants of unknown significance are not necessarily clinically meaningful. The changes in the practice of the other respondents may be in some part reflective of their lack of familiarity with the new data. The results of this survey may provide insight into the changes in practice patterns of pediatric oncologists as genomic medicine becomes more commonly incorporated into the management of children and young adults diagnosed with rare cancers.
A frequent source of concern among respondents was the discussion with the family about the meaning of a mutation of unknown significance. These results highlight that genomic analyses have increasing sensitivity to detect genomic alterations but at times do not detail whether these results are pathogenic or represent normal variations. These data may create greater ambiguity and confusion. 6, 9 Gray et al 10 reported on a survey of 160 physicians assessing their current use of somatic testing, their attitudes about multiplex testing, and their genomic confidence. Twenty-two percent of the physicians endorsed low confidence in their ability to interpret genomic data, and only 42% reported that they disclosed uncertain genomic findings to patients. When the ambiguity regarding the meaning of the variants of unknown significance was removed and the respondents were told that all the mutations constituting the 10% rate were pathogenic, 84% of the respondents who were previously unsure now stated that they would offer testing.
The presentation of the new data, including variants of unknown significance, was associated with an increased proportion of providers who would offer TP53 testing. It is possible that some providers believe a proportion of these mutations in time may be determined to be pathogenic as well. Xu et al 11 performed whole genome or whole exome sequencing in 1120 patients younger than 20 years with cancer. In addition to pathogenic mutations, they found 226 variants of uncertain significance in 60 genes that have been associated with cancer predisposition syndromes. Of the 226, 119 (10% of patients) were determined to be deleterious by at least 2 computational methods, and they may confer a susceptibility to cancer. In this survey, when providers were given a scenario in which all the mutations constituting the 10% rate were pathogenic, the majority of the respondents stated that they would offer TP53 mutation testing to their patients, and this suggests a possible threshold at which most providers would offer testing. In this survey, we did not question the respondents directly regarding whether they had a percentage of affected patients with deleterious TP53 mutations that would induce them to test all patients. As such, the increase in the number of respondents willing to offer TP53 testing may reflect a limitation of a survey instrument and potential conditioning of the respondents by the order of the survey questions.
The American Society of Clinical Oncology, the American Academy of Pediatrics, and the American College of Medical Genetics and Genomics have published guidelines for testing children for genetic syndromes. 12 In general, genetic testing in children is reserved for diagnostic testing in children with signs or symptoms of a genetic syndrome or for predictive testing in asymptomatic children with a positive family history of a specific syndrome. However, predictive testing is recommended only if the disease will manifest during childhood and if there are safe and effective screening and intervention options available that will reduce morbidity or mortality, as in the case of LFS. 13 The 2 factors that providers most frequently took into consideration when deciding whether to offer germline mutation testing were potential implications for other Original Article family members and the possibility that surveillance imaging for patients with LFS would detect new malignancies at an earlier stage. Similarly, these data coincide with a study by Alderfer et al 14 assessing parental perceptions of the benefits of TP53 testing: the most commonly reported advantages of testing were satisfying a need to know, promoting the health of the child and enabling the child to get appropriate medical surveillance, and assessing the risk for other family members.
Genetic testing has several potential benefits for patients with osteosarcoma. Individuals with TP53 mutations are younger at diagnosis than those without the mutation, and these individuals and their family members are at increased risk of developing other LFS-associated cancers. 5 Finding a germline TP53 mutation can potentially affect clinical practice, including the avoidance of radiation therapy, 2 the choice of chemotherapy regimens, and the benefits of tumor surveillance.
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The current study is limited by its sample size. However, providers from varied backgrounds, working in varied practices, participated in the survey. Nevertheless, the response rate of 22% may have led to a selection bias for those respondents who are more invested in the treatment of patients with osteosarcoma or inherited cancer predisposition syndromes. The respondents who identified themselves as specializing in sarcoma demonstrated very little change in their choice about offering TP53 testing when they were presented with the new data, and this may be reflective of their familiarity with these data. This may affect the broader generalizability of the findings from this survey because it may underestimate the effect of introducing the new data on the broader community of oncologists treating patients with osteosarcoma. Conversely, those who worked in an institution with a cancer predisposition clinic were more likely to offer TP53 testing when they were presented with the prior data and the new data, and this serves to overestimate the effect of the presentation of these data. Another potential confounding variable associated with this survey instrument is that all the respondents received the questions in the same order. As noted previously, this may have conditioned the respondents to consider a 10% rate of deleterious TP53 mutations to be a clinically significant proportion. This is potentially evidenced by the fact that 71% of the respondents who would not have performed TP53 testing when they were presented with the new data changed their answer when they were presented with the scenario in which they were told that all the mutations were deleterious. Further research is warranted to evaluate what proportion of patients with a deleterious mutation would drive respondents to test the entire population. This survey was primarily focused on whether the wide dissemination of currently available data would affect practice patterns. An additional limitation of the study is the scope of the survey because hypothetical cases may not accurately reflect the providers' true practice patterns with real patients. For example, if the age of the patient presented in our cases had been less than 10 years, that is, much younger than the typical age of onset of 15 years, a different perspective on the need to offer testing may have been observed.
In conclusion, recent data increase the proportion of providers willing to offer TP53 testing, and this suggests a concern by pediatric oncologists that variants of unknown significance may be disease-defining in rare cancers. In the current era of genomic medicine, clinicians are going to increasingly encounter variants of unknown significance in the presence of disease. Further research and registries are needed to continue tabulating these variations and to define the likelihood of pathogenesis. The Children's Oncology Group has recently established Project: Every Child as a childhood cancer registry and biobank. Because of the uncertainty and ambivalence regarding variants of unknown significance demonstrated in this study, one of the goals of this initiative is to obtain parental germline DNA, which is a vital area of research for distinguishing between variants of unknown significance and diseasepredisposing mutations.
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